Serotonin Function in Obsessive-Compulsive Disorder: A Comparison of the Effects of Tryptophan and m-Chlorophenylpiperazine in Patients and Healthy Subjects

Archives of General Psychiatry

Volumn 45, Issue 2, 1988, Pages 177-185

  Charney, Dennis S ^a   Goodman, Wayne K ^a   Price, Lawrence H ^a   Woods, Scott W ^a   Rasmussen, Steven A ^b   Heninger, George R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PROLACTIN; SEROTONIN; TRYPTOPHAN;

ADULT; CLINICAL ARTICLE; COMPULSION; FEMALE; HUMAN; MALE; OBSESSION;

ADULT; COMPARATIVE STUDY; FEMALE; GROWTH HORMONE; HUMAN; HYDROCORTISONE; MALE; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY INVENTORY; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, SEROTONIN; SEROTONIN; SEX FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRYPTOPHAN;

EID: 0023860008     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1988.01800260095012     Document Type: Article

References (85)

1. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-958.
2. Insel TR, Mueller EA III, Gillin JC, Siever LJ, Murphy DL: Biological markers in obsessive-compulsive and affective disorders. J Psychiatr Res 1984;18:407-423.
3. Turner SM, Beidel DC, Nathan RS: Biological factors in obsessive-compulsive disorders. Psychol Bull 1985;97:430-450.
4. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL: Obsessive-compulsive disorder and serotonin: Is there a connection? Biol Psychiatry 1985;20:1174-1188.
5. Ananth J, Pecknold JC, van der Steen N, Engelsmann F: Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol Biol Psychiatry 1981;5:257-264.
6. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M: Clomipramine treatment of childhood obsessive compulsive disorder: A double-blind controlled study. Arch Gen Psychiatry 1985;42:977-983.
7. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M: Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612.
8. Marks IM, Stern R, Mawson D, Cobb J, McDonald R: Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 1980;136:1-25.
9. Montgomery SA: Clomipramine in obsessional neurosis: A placebo controlled trial. Pharmacol Med 1980;1:189-192.
10. Renynghe de Voxrie GV: Anafranil (G 34586) in obsessive neurosis. Acta Neurol Belg 1968;68:787-792.
11. Stern RS, Marks IM, Wright J, Luscombe DK: Clomipramine: Plasma levels, side effects and outcome in obsessive-compulsive neurosis. Postgrad Med J 1980;56:134-139.
12. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L: Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285.
13. Volavka J, Neziroglu F, Yaryura-Tobias JA: Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;14:83-91.
14. Yaryura-Tobias JA, Neziroglu F, Bergman L: Chlorimipramine, for obsessive-compulsive neurosis: An organic approach. Curr Ther Res 1976;20:541-548.
15. Zohar J, Insel TR: Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22:667-687.
16. Kahn RS, Westenberg HGM, Jolles J: Zimelidine treatment of obsessive-compulsive disorder. Acta Psychiatr Scand 1984;69:259-261.
17. Prasad A: A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry 1984;17:61-62.
18. Fontaine R, Chouinard G: Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:605-608.
19. Turner SM, Jacob RG, Beidel DC, Himmelhoch J: Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1985;5:207-212.
20. Price LH, Goodman WK, Charney DS, Heninger GR: Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987;144:1059-1061.
21. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L: Clomipramine treatment of obsessive compulsive disorder: II. Biochemical aspects. Arch Gen Psychiatry 1980;37:1289-1294.
22. Flament MF, Rapoport JL, Murphy DL, Big CT, Lake CR: Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987;44:219-225.
23. Weizmann A, Carmi M, Hermesh H, Shahar A, Apter A, Tyano S, Rehavi M: High affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 1986;143:335-339.
24. Yaryura-Tobias JA, Bebirian RJ, Neziroglu FA, Bhagavan HN: Obsessive-compulsive disorders as a serotonergic defect. Res Commun Psychol Psychiatry Behav 1977;2:279-286.
25. Shillitoe EE: The effect of parachlorphenylalanine on social interaction of male rats. Br J Pharmacol 1970;38:305-315.
26. Abel EL: Drugs and Behavior: A Primer in Neuropsychopharma cology. New York, John Wiley & Sons Inc, 1974.
27. Geyer MA, Puerto DB, Menkes DB, Segal DS, Mandell AJ: Behavioral studies following lesions of mesolimbic and mesostriatal serotonergic pathways. Brain Res 1976;106:257-270.
28. Wirtshafter D, Asin KE, Kent EW: An analysis of open field hyperactivity following electrolytic median raphe lesions in the rat, abstracted. Soc Neurosci 1980;6:422.
29. Gately PF, Poon SL, Segal DS, Geyer MA: Depletion of brain serotonin by 5,7-dihydroxytryptamine alters the response to amphetamine and the habituation of locomotor activity in rats. Psychopharmacology 1985;87:400-405.
30. Valzelli L: Reflections on experimental and human pathology of aggression. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:311-325.
31. Asberg M, Traskman L, Thoren P: 5-HIAA in the cerebrospinal fluid: A biochemical suicide predictor? Arch Gen Psychiatry 1976;33:1193-1197.
32. Bioulac B, Benezech M, Renaud B, Noel B, Roche D: Serotonergic dysfunction in the 47,XYY syndrome. Biol Psychiatry 1979;15:917-923.
33. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF: Aggression in human correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1:131-139.
34. Agren H: Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: II. Suicide. Psychiatry Res 1980;3:225-235.
35. Oreland L, Wiberg A, Asberg M, Traskman L, Sjostrand L, Thoren P, Bertilsson L, Bring GT: Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Res 1981;4:21-29.
36. Valzelli L: Psychopharmacology of aggression: An overview. Int Pharmacopsychiatry 1981;16:39-48.
37. Traskman L, Asberg M, Bertilsson L, Sjostrand L: Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981;38:631-636.
38. Banki CM, Molnar G, Vojnik H: Cerebrospinal fluid amine metabolites, tryptophan, and clinical parameter in depression: II. Psychopathological symptoms. J Affective Disord 1981;3:91-99.
39. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klien WJ, Bunney WE, Goodwin FK: Aggression, suicide, and serotonin: Relationships in CSF amine metabolites. Am J Psychiatry 1982;139:741-746.
40. Van Praag HM: Depression, suicide and metabolism of serotonin in the brain. J Affective Disord 1982;4:275-290.
41. Muhlbauer HD: Human aggression and the role of central serotonin. Pharmacopsychiatry 1985;18:218-221.
42. Mueller EA, Murphy DL, Sunderland T: Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 1986;89:388-391.
43. Charney DS, Heninger GR, Reinhard JF, Sternberg DE, Hafstaad KM: The effect of intravenous L-tryptophan on prolactin and growth hormone and mood in healthy subjects. Psychopharmacology 1982;77:217-222.
44. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
45. Hamilton M: Diagnosis and ratings of anxiety. Br J Psychiatry 1969;3:76-79.
46. Weiner RI, Ganong WF: Monoamines and histamine in regulation of anterior pituitary secretion. Physiol Rev 1978;58:905-976.
47. Birge CA, Jacobs LS, Hammer CT, Daughaday WH: Catecholamine inhibition of prolactin secretion by isolated rat adenohypophyses. Endocrinology 1970;86:120-130.
48. Clemens JA, Roush ME, Fuller RW: Evidence that serotonin neurons stimulate secretion of prolactin releasing factor. Life Sci 1978;22:2209-2213.
49. Garthwaite TL, Hagen TC: Evidence that serotonin stimulates a prolactin-releasing factor in the rat. Neuroendocrinology 1979;29:215-230.
50. Kamberi IA, Mical RS, Porter JC: Effect of melatonin and serotonin on the release of FSH and prolactin. Endocrinology 1971;88:1288-1293.
51. Kordon C, Blake CA, Terkel J, Sawyer CH: Participation of serotonin containing neurons in the suckling-induced rise in plasma prolactin levels in lactating rats. Neuroendocrinology 1973;13:213-223.
52. Advis JP, Simpkins G, Meites J: Serotonergic control of prolactin release in male rats. Life Sci 1979;24:359-366.
53. Lamberts SWJ, MacLeod RM: The interaction of serotonergic and dopaminergic systems on prolactin secretion in the rat. Endocrinology 1978;103:287-295.
54. Meites J, Simpkins J, Bruni J, Advis J: Role of biogenic amines in control of anterior pituitary hormones. Int Res Commun J Med Sci 1977;5:1-7.
55. Mueller GP, Twohy CP, Chen HT, Advis JP, Meites J: Effect of L-tryptophan and restraint stress on hypothalamine and brain serotonin turnover, and pituitary TSH and prolactin release in rats. Life Sci 1976;18:715-724.
56. Van de Kar LD, Bethea CL: Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus. Neuroendocrinology 1982;35:225-230.
57. Caccia S, Fong MH, Garattini Zanini MG: Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone. J Pharm Pharmacol 1982;34:605-606.
58. Caccia S, Ballabio M, Samanin R: (-)-m-Chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 1981;33:477-478.
59. Fuller RW, Snoddy HD, Mason NR, Owen JE: Disposition and pharmacological effects of m-chlorophenylpiperazine in rats. Neuropharmacology 1981;20:155-162.
60. Invernizzi R, Cotecchia S, DeBlasi A, Mennini T, Pataccini R, Samanin R: Effects of m-chlorophenylpiperazine on receptor binding and brain metabolism of monoamines in rats. Neurochem Int 1981;3:239-244.
61. Samanin R, Mennini T, Ferraris A: m-Chlorophenylpiperazine: A central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol 1979;308:159-163.
62. Sills MA, Wolfe BB, Frazer A: Determination of selective and nonselective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 1984;231:480-487.
63. Peroutka SJ: Selective labeling of 5-HT1A and 5-HT1B binding sites in bovine brain. Brain Res 1985;344:167-171.
64. Todd RD, Ciaranello RD: Multiple high-affinity 3H-serotonin binding sites in human frontal cortex. Brain Res 1987;400:247-258.
65. Heninger GR, Charney DS, Smith A: Effects of serotonin receptor agonists and antagonists on neuroendocrine function in rhesus monkeys. Soc Neurosci Abstr, in press.
66. Fernstrom JD: Acute effects of tryptophan and single meals on serotonin synthesis in the rat brain, in Ho BT, Schoolar JC, Usdin E (eds): Serotonin in Biological Psychiatry. New York, Raven Press, 1982, pp 85-106.
67. Fernstrom JD, Wurtman RJ: Brain serotonin content: Physiological dependence on plasma tryptophan levels. Science 1971;173:149-152.
68. Lookingland KJ, Shannon NJ, Chapin DS, Moore KE: Exogenous tryptophan increases synthesis, storage, and intraneuronal metabolism of 5-hydroxytryptamine in the rat hypothalamus. J Neurochem 1986;47:205-212.
69. Charney DS, Heninger GR, Sternberg DE: Serotonin function and mechanism of action of antidepressant treatment: Effects of amitriptyline and desipramine. Arch Gen Psychiatry 1984;41:359-365.
70. Price LH, Charney DS, Heninger GR: Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 1985;37:809-818.
71. Baumann P: Transport systems and enzymes involved in the metamorphosis of tryptophan into serotonin. Pharmacopsychiatry 1985;18:188-192.
72. Marsden CA, Curzon G: The contribution of tryptamine in the behavioural effects of L-tryptophan in tranylcypromine-treated rats. Psychopharmacology 1978;57:71-76.
73. Wurtman RJ, Larin F, Mostafapour S, Fernstrom JD: Brain catechol synthesis: Control by brain tyrosine concentration. Science 1974;185:183-184.
74. Carlsson M, Svensson K, Eriksson E, Carlsson A: Rat brain serotonin: Biochemical and functional evidence for a sex difference. J Neural Transm 1985;63:297-313.
75. Munaro NI: The effect of ovarian steroids on hypothalamic 5-hydroxytryptamine neuronal activity. Neuroendocrinology 1978;26:270-276.
76. Fischette CT, Biegon A, McEwen BS: Sex steroid modulation of the serotonin behavioral syndrome. Life Sci 1984;35:1997-2006.
77. Van de Kar LD, Karteszi M, Bethea CL, Ganong WF: Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 1985;41:380-384.
78. Van de Kar LD, Wilkinson CW, Skrobik Y, Brownfield MS, Ganong WF: Evidence that serotonergic neurons in the dorsal raphe nucleus exert a stimulatory effect on the secretion of renin but not of corticosterone. Brain Res 1982;235:233-243.
79. Gibbs DM, Vale W: Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophyseal portal blood. Brain Res 1983;280:176-179.
80. Fuller RW, Snoddy HD: Effect of serotonin-releasing drugs on serum corticosterone concentration in rats. Neuroendocrinology 1980;31:96-100.
81. Fuller RW: Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 1981;32:118-127.
82. Meites J, Sonntag WE: Hypothalamic hypophysiotropic hormones and neurotransmitter regulation: Current views. Annu Rev Pharmacol Toxicol 1981;21:295-322.
83. Dorsa DM, Conners MH: Canine growth hormone responsiveness during pentobarbital anesthesia: A method for evaluating serotonergic stimulatory action. Endocrinology 1979;104:101-106.
84. Schotte A, Maloteaux JM, Laduron PM: Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res 1983;276:231-235.
85. Robaut C, Fillion MP, Dufois S, Fayolle-Bauguen C, Rousselle JC, Gillet G, Benkirane S, Fillion G: Multiple high affinity binding sites for 5-hydroxytryptamine: A new class of sites distinct from 5-HT1 and S2. Brain Res 1985;346:250-262.